Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 90%

ReporterLens™ analysis of "Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 90%" — CNBC. Analyst archetype. Emotional tone 2/10. Attribution 9/10. Headline accuracy 8/10. Read the full ReporterLens™ breakdown of sourcing, evidence, and narrative framing.